Pharma Technology Investment Trends - Executive Director in Translational Oncology, Top 10 Pharma

An executive director of translational oncology at a major pharma company speaks to how they currently see investments in the precision medicine / oncology space unfolding now and in the next 3 – 5 years. In addition to being a translational lead, they are a diagnostic lead for multiple cancer indications, as well as in the rare disease space. Their company currently invests the most in genomics and liquid biopsy, clinical trial operations, and companion diagnostics. These areas have clear returns in the form of supporting drug development and finding novel treatment targets. They also view supply chain investments as being a top source of ROI, though not holding as significant of an investment share. Trends such as increasing diagnostic regulations(e.g., IVDR), emerging therapeutic modalities, and decentralized care and monitoring have potential to alter spending decisions. Increasing regulation is a pain point in this expert’s opinion, as there is a lack of clarity in how regulations will define the utility of some technologies, for instance, liquid biopsy to stratify patients.

‍